Mohammad Aarif Siddiqui1,2, Paradesi Naidu Gollavilli2, Vignesh Ramesh2, Beatrice Parma2, Annemarie Schwab2, Maria Eleni Vazakidou2, Ramakrishnan Natesan3, Ozge Saatci4, Ida Rapa5, Paolo Bironzo5, Harald Schuhwerk6, Irfan Ahmed Asangani3, Ozgur Sahin4, Marco Volante5, Paolo Ceppi7,8. 1. Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark. 2. Interdisciplinary Center for Clinical Research (IZKF), Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany. 3. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 4. Department of Drug Discovery and Biomedical Sciences, University of South Carolina, Columbia, SC, USA. 5. Department of Oncology at San Luigi Hospital, University of Turin, Orbassano, Turin, Italy. 6. Department of Experimental Medicine-I, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany. 7. Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark. pceppi@bmb.sdu.dk. 8. Interdisciplinary Center for Clinical Research (IZKF), Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany. pceppi@bmb.sdu.dk.
Abstract
BACKGROUND: Epithelial-to-mesenchymal transition (EMT) enhances motility, stemness, chemoresistance and metastasis. Little is known about how various pathways coordinate to elicit EMT's different functional aspects in non-small cell lung cancer (NSCLC). Thymidylate synthase (TS) has been previously correlated with EMT transcription factor ZEB1 in NSCLC and imparts resistance against anti-folate chemotherapy. In this study, we establish a functional correlation between TS, EMT, chemotherapy and metastasis and propose a network for TS mediated EMT. METHODS: Published datasets were analysed to evaluate the significance of TS in NSCLC fitness and prognosis. Promoter reporter assay was used to sort NSCLC cell lines in TSHIGH and TSLOW. Metastasis was assayed in a syngeneic mouse model. RESULTS: TS levels were prognostic and predicted chemotherapy response. Cell lines with higher TS promoter activity were more mesenchymal-like. RNA-seq identified EMT as one of the most differentially regulated pathways in connection to TS expression. EMT transcription factors HOXC6 and HMGA2 were identified as upstream regulator of TS, and AXL, SPARC and FOSL1 as downstream effectors. TS knock-down reduced the metastatic colonisation in vivo. CONCLUSION: These results establish TS as a theranostic NSCLC marker integrating survival, chemo-resistance and EMT, and identifies a regulatory network that could be targeted in EMT-driven NSCLC.
BACKGROUND: Epithelial-to-mesenchymal transition (EMT) enhances motility, stemness, chemoresistance and metastasis. Little is known about how various pathways coordinate to elicit EMT's different functional aspects in non-small cell lung cancer (NSCLC). Thymidylate synthase (TS) has been previously correlated with EMT transcription factor ZEB1 in NSCLC and imparts resistance against anti-folate chemotherapy. In this study, we establish a functional correlation between TS, EMT, chemotherapy and metastasis and propose a network for TS mediated EMT. METHODS: Published datasets were analysed to evaluate the significance of TS in NSCLC fitness and prognosis. Promoter reporter assay was used to sort NSCLC cell lines in TSHIGH and TSLOW. Metastasis was assayed in a syngeneic mouse model. RESULTS:TS levels were prognostic and predicted chemotherapy response. Cell lines with higher TS promoter activity were more mesenchymal-like. RNA-seq identified EMT as one of the most differentially regulated pathways in connection to TSexpression. EMT transcription factors HOXC6 and HMGA2 were identified as upstream regulator of TS, and AXL, SPARC and FOSL1 as downstream effectors. TS knock-down reduced the metastatic colonisation in vivo. CONCLUSION: These results establish TS as a theranostic NSCLC marker integrating survival, chemo-resistance and EMT, and identifies a regulatory network that could be targeted in EMT-driven NSCLC.
Authors: Valentina Monica; Giorgio V Scagliotti; Paolo Ceppi; Luisella Righi; Alberto Cambieri; Marco Lo Iacono; Silvia Saviozzi; Marco Volante; Silvia Novello; Mauro Papotti Journal: Clin Cancer Res Date: 2009-12-15 Impact factor: 12.531
Authors: S-Q Liang; T M Marti; P Dorn; L Froment; S R R Hall; S Berezowska; G Kocher; R A Schmid; R-W Peng Journal: Cell Death Dis Date: 2015-07-16 Impact factor: 8.469
Authors: V Tirino; R Camerlingo; K Bifulco; E Irollo; R Montella; F Paino; G Sessa; M V Carriero; N Normanno; G Rocco; G Pirozzi Journal: Cell Death Dis Date: 2013-05-02 Impact factor: 8.469
Authors: Hui Huang; Zhengyuan Huo; Jiantong Jiao; Wei Ji; Jin Huang; Zheng Bian; Bin Xu; Junfei Shao; Jun Sun Journal: Cancer Cell Int Date: 2022-04-29 Impact factor: 6.429